First head-to-head study in people living with obesity shows tirzepatide results in around 50% more weight loss than semaglutide A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss of 20.2%, 47% higher than the 13.7% average weight loss for semaglutide
With a delayed-release capsule, these probiotics reach your gut effectively, ensuring you get the maximum benefits
Impact on Reward Pathways : Research suggests that semaglutide may also affect the brains reward pathways, reducing the pleasure associated with eating, particularly high-calorie, high-fat foods
After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg once weekly
Our expert team provides cutting-edge treatments to support your journey, alongside nutrition counseling to ensure you maintain a balanced, sustainable lifestyle